Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

Eculizumab effectively reduced MG-ADL scores and corticosteroid use in thymoma-associated myasthenia gravis patients by week 12. The monoclonal antibody targets complement protein C5, preventing ...

In the U.S., EPYSQLI (eculizumab-aagh) was approved by the U.S. Food and Drug Administration (FDA) as a biosimilar to Soliris ® (eculizumab) in July 2024 for the treatment of patients with paroxysmal ...

There is an approved treatment — a therapeutic antibody called eculizumab — but its half-life of only 11.3 days means patients need to endure transfusion every two weeks. In 2018, researchers ...

Recent off-label use of a complement inhibiting drug, eculizumab (CD55 inhibitor) was shown to provide a dramatic benefit in patients with CHAPLE disease with an immediate correction of ...